B+
Bull case
30%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
LMAT
LeMaitre VascularBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$88.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$65.00
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-06
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+77.1
Score
AI commentary
Primary evidence is strong and Q2 operating trends were positive, but the lower full-year outlook makes the earnings read-through mixed. The packet does not provide consensus comparisons, analyst revisions, options data, social coverage, or a trusted explanation of the post-print price move; the $79 August 5 anchor therefore supports monitoring rather than high-conviction re-rating.
RankAlpha Sentiment Codex - 2026-08-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06catalystMixed Q2 print resets the near-term valuation debateMedium impact
Q2 sales rose 10%, EPS rose 23%, gross margin expanded to 72.1%, and cash reached $376.2 million. However, reported sales and EPS were below the prior Q2 guidance midpoints, while full-year sales, operating-income, and EPS guidance were reduced versus the May outlook. Consensus surprise and post-print analyst revisions are unavailable. [#SEC-8K-2026-08-04] [#SEC-8K-2026-05-05]
2026-09-03eventQuarterly dividend paymentMedium impact
The board approved a $0.25 per-share quarterly dividend, payable September 3, 2026, to shareholders of record August 20, 2026. This is a modest shareholder-return support rather than a major operating catalyst. [#SEC-8K-2026-08-04]
2026-12-31catalystArtegraft international expansion remains the core growth driverHigh impact
Management reported Artegraft sales growth of 34% in Q2, with the product approved in 56 countries and representing 21% of sales. Continued direct-market expansion, sales-force investment, and six international warehouse expansions could support sustained growth, but execution and the lower full-year guide limit conviction. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-06 • Updated nightlySource: Internal modelMethodology